A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.
Schimanski, CC; Kasper, S; Hegewisch-Becker, S; Schroeder, J; Overkamp, F; Kullmann, F; Bechstein, WO; Voehringer, M; Oellinger, R; Lordick, F; Heinemann, V; Geissler, M; Schulz-Abelius, A; Linz, B; Bernhard, H; Schoen, MR; Greil, R; Smith-Machnow, V; Schmidtmann, I; Moehler, MH J CLIN ONCOL. 2019; 37(15):
Antihormones with or without irradiation in breast cancer: 10-year results of the ABCSG 8A trial
Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Solkner, L; Greil, R; Jakesz, R; Kwasny, W; Heck, D; Bjelic-Radisic, V; Balic, M; Stoger, H; Wieder, U; Zwrtek, R; Semmler, D; Horvath, W; Melbinger-Zeinitzer, E; Wiesholzer, M; Wette, V; Gnant, M RADIOTHER ONCOL. 2019; 133: S132-S133.
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
Keil, F; Hartl, M; Altorjai, G; Pecherstorfer, M; Mayrbaurl, B; de Vries, A; Berghold, A; Riedl, R; Fridrik, MA; Fuereder, T; Burian, M; Greil, R J CLIN ONCOL. 2019; 37(15):
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R-2-CHOP in subjects with previously untreated, high-risk DLBCL.
Nowakowski, GS; Willenbacher, W; Greil, R; Larsen, TS; Patel, K; Jager, U; Manges, RF; Trumper, LH; Haioun, C; Everaus, H; Kalakonda, N; Knoble, J; Brown, P; Joergensen, JM; Cunningham, D; Domper, N; Casadebaig, ML; Manzke, O; Munoz, J J CLIN ONCOL. 2019; 37(15):
Treatment with 5-Azacytidine results in expression of long terminal repeat (LTR) elements in peripheral blood mononuclear cells of patients with MDS and AML: first pilot study
Daskalakis, M; Haubitz, M; Steiner, D; Helf, M; Brocks, D; Pleyer, L; Greil, R; Plass, C; Baerlocher, GM; Leibundgut, EO SWISS MED WKLY. 2019; 149: 22S-22S.
Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years
Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Fitzal, F; Bago-Horvath, Z; Singer, C; Hlauschek, D; Kronenwett, R; Bernhisel, R; Lancaster, J; Gnant, M CANCER RES. 2019; 79(4):
The impact of clinical risk assessment versus PAM-50 ROR score on prognosis and therapeutic decision making in patients with hormone-receptor positive early stage breast cancer
Devyatko, Y; Filipits, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, C; Fitzal, F; Steger, G; Gray, B; Ferree, S; Fesl, C; Soelkner, L; von Minckwitz, G; Gnant, M CANCER RES. 2019; 79(4):
Vergleich der Hochtontherapie und der TENS Therapie bei chemotherapieinduzierter Polyneuropathie – Projekt HIT-CIPN – Studienprotokoll eines RCT
Johansson T; Schaffler-Schaden D; Herfert J; Sassmann R; Gampenrieder SP; Rinnerthaler G; Lampl K; Rieder F; Flamm M; Greil R; Niebauer J DOI: 10.3205/19degam158. 2019; -53. Kongress für Allgemeinmedizin und Familienmedizin. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) _x000D_ ; 12.-14.09.2019; Erlangen.
A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial
Gampenrieder, S; Angela, R; Rinnerthaler, G; Hackl, H; Steiner, M; Pulverer, W; Weinhaeusel, A; Klinglmayr, E; Karl, T; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R CANCER RES. 2019; 79(4):
Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R CANCER RES. 2019; 79(4):